Price
$5.35
Decreased by -1.83%
Dollar Volume (20D)
32.89 K
ADR%
6.43
Earnings Report Date (estimate)
Mar 28, 24
Shares Float
4.19 M
Shares Outstanding
5.43 M
Shares Short
96.18 K
Market Cap.
29.59 M
Beta
0.17
Price / Earnings
N/A
20D Range
4.9 6.4
50D Range
4.9 8.85
200D Range
2.83 8.85
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.86
Increased by +64.17%
-1.16
Increased by +25.86%
Aug 10, 23 -0.87
Increased by +95.56%
-1.42
Increased by +38.73%
May 15, 23 -1.34
Increased by +81.39%
-1.5
Increased by +10.67%
Mar 30, 23 -0.92
Increased by +87.22%
-3.08
Increased by +70.13%
Nov 9, 22 -2.4
Increased by +73.33%
-5.5
Increased by +56.36%
Aug 11, 22 -19.6
Decreased by -104.17%
-7.5
Decreased by -161.33%
May 16, 22 -7.2
Increased by +21.74%
-7.6
Increased by +5.26%
Mar 15, 22 -7.2
Increased by +50.68%
-8.8
Increased by +18.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-3.2 M
Increased by +23.26%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-3.26 M
Increased by +96.68%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-4.15 M
Increased by +47.72%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-110.78 M
Decreased by -1.33 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-4.18 M
Increased by +55.82%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-98.31 M
Decreased by -859.04%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-7.94 M
Increased by +17.89%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-7.76 M
Increased by +49.62%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.